BTK and mantle cell lymphoma: In Europe, brexucabtagene autoleucel was approved in December 2020 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after ≥ 2 lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor [3, 4].